TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00439101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megstrol Acetate
Description: Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
Study: NCT03847103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Stimulation Program
Description: 10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor Stimulation Program
Description: 10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
Study: NCT05376709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short-Term Calorie Reduction
Description: Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
Study: NCT01642914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 micrograms
Description: oral capsule, taken once daily each morning at least 30 minutes before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 micrograms
Description: oral capsule, taken once daily each morning at least 30 minutes before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: oral capsule, taken once daily each morning at least 30 minutes before breakfast
Study: NCT04317183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chamomile topical oral gel
Description: Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chamomile topical oral gel
Description: Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Topical Gel
Description: topical anti fungal agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Topical Gel
Description: topical anti fungal agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent
Study: NCT05141734

Intervention type: DIAGNOSTIC_TEST
Intervention: The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)
Description: The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
Study: NCT04317183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracure gel
Description: Topical analgesic gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure gel
Description: Topical analgesic gel
Study: NCT00671138

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Necator americanus
Description: 10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham inoculation
Description: A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
Study: NCT03516396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Plus
Description: Training plus enhanced community development activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Only
Description: Training Only (livestock management and child nutrition) for 24 months then add community development inputs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Inputs then Community development and training
Description: No inputs for 24 months then add community development and training
Study: NCT02289235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger powder capsule 1000 mg twice daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder 2 capsules twice daily for 3 months
Study: NCT01604590

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
Study: NCT03694366

Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers

Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers

Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers

Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers
Study: NCT00317252

Intervention type: DRUG
Group type: OTHER
Intervention: Hold ACEI or ARB
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hold ACEI or ARB
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
Study: NCT02511899

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mango fruit powder
Description: Dietary supplement; Mango fruit powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mango fruit powder
Description: Dietary supplement; Mango fruit powder
Study: NCT01754116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30 mg oral
Description: GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg oral + GSK1265744 30mg oral
Description: Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 400 mg (200 nm)
Description: A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 400 mg (1 micro m)
Description: A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 400 mg (5 micro m)
Description: A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
Study: NCT01466452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: single-dose aspirin in 100 mg 1 tablet every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: single-dose aspirin 200 mg 1 tablet every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: double-dose aspirin 100 mg 1 tablet every 12 hours
Study: NCT04890951

Intervention type: PROCEDURE
Intervention: Hysteropexy
Description: Uterine preservation through suspension

Intervention type: PROCEDURE
Intervention: Hysterectomy and vaginal vault suspension
Description: Uterine removal and sewing the vagina upwards
Study: NCT01874795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
Study: NCT03241381

Intervention type: DIAGNOSTIC_TEST
Intervention: vitamin D serum assay study and control groups
Description: Serum- vitamin D assay

Intervention type: DIAGNOSTIC_TEST
Intervention: vitamin D serum assay study and control groups
Description: Serum- vitamin D assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Photometry
Description: Serum- Hemoglobin assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Photometry
Description: Serum- Hemoglobin assay

Intervention type: OTHER
Intervention: Russels periodontal index
Description: Clinical examination for periodontitis

Intervention type: OTHER
Intervention: Russels periodontal index
Description: Clinical examination for periodontitis
Study: NCT00393029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
Study: NCT02227472

Intervention type: OTHER
Intervention: Evaluation of cognitive and pre-academic skills
Description: Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).

Intervention type: OTHER
Intervention: Parent questionnaires
Description: Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
Study: NCT02992704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2A
Description: peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2A
Description: peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
Study: NCT03242304

Intervention type: OTHER
Intervention: Behavioral tests
Description: We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.

Intervention type: OTHER
Intervention: Behavioral tests
Description: We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
Study: NCT02819349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting for Relapse Prevention (T4RP)
Description: T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
Study: NCT02494219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Immunochromatographic streptococcal test
Description: Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
Study: NCT04433156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04137497

Intervention type: DIAGNOSTIC_TEST
Intervention: The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)
Description: All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)
Description: All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)
Description: All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
Study: NCT01471756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Procedure as described in ARM
Description: Standard of Care Procedure as described in ARM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Procedure as described in ARM
Description: Standard of Care Procedure as described in ARM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Procedure as described in ARM
Description: Standard of Care Procedure as described in ARM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Procedure as described in ARM
Description: Standard of Care Procedure as described in ARM
Study: NCT01629316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text reminders, counseling, and link coordination
Description: This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care - control arm
Description: The control arm is standard of care for each subject.
Study: NCT02267824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraoral OrthoPulse® PBM
Description: Patients carry out daily extraoral OrthoPulse® PBM treatments at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic Appliance Treatment
Description: Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
Study: NCT02885649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo partial or radical nephrectomy
Study: NCT04761874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telestroke
Description: In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
Study: NCT01599130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: entecavir 0.5mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180ug per week
Study: NCT02512536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
Study: NCT00439101

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (lemon-lime suspension) taken orally for 90 days.
Study: NCT02542059

Intervention type: RADIATION
Intervention: 68Ga-exendin PET/CT
Description: 68Ga-exendin PET/CT
Study: NCT02642536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MH MOVE
Description: provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
Study: NCT01246622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study: NCT00755859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids plus azathioprine
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
Study: NCT02836626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep fascial mobilization
Description: Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superficial fascial mobilization
Description: This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.